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Abstract
Aims This pilot study was designed to evaluate the feasibility
and benefits of electronic adherence monitoring of antiretro-
viral medications in HIV patients who recently started Highly
Active Anti Retroviral Therapy (HAART) in Francistown,
Botswana and to compare this with self-reporting.
Methods Dosing histories were compiled electronically
using Micro Electro Mechanical Systems (MEMS) mon-
itors to evaluate adherence to prescribed therapies. Thirty
patients enrolled in the antiretroviral treatment program
were monitored over 6 weeks. These patients were all
antiretroviral (ARV) naïve. After each visit (mean three
times) to the pharmacy, the data compiled by the monitors
were downloaded. Electronic monitoring of adherence was
compared to patient self-reports of adherence.
Results The mean individual medication adherence level
measured with the electronic device was 85% (range 21–
100%). The mean adherence level measured by means of
self-reporting was 98% (range 70–100%). Medication
prescribed on a once-a-day dose base was associated with
a higher adherence level (97.9% for efavirenz) compared
with a twice-a-day regimen (88.4% for Lamivudine/
Zidovudine).
Conclusions It is feasible to assess treatment adherence
of patients living in a low resource setting on HAART
by using electronic monitors. Adherence, even in the
early stages of treatment, appears to be insufficient in
some patients and may be below the level required for
continuous inhibition of viral replication. This approach
may lead to improved targeting of counselling about
their medication intake of such patients in order to
prevent occurrence of resistant viral strains due to
inadequate inhibition of viral replication. In this pilot
study a significant difference between the data recorded
through the electronic monitors and those provided by
self-reporting was observed.
Keywords HAART.MEMSCAPS.Adherence
Introduction
Botswana is one of the countries worst affected by the HIV
pandemic with a prevalence of approximately 17% of the
entire population [1]. An estimated 38.5% of those aged
15–49 years are HIV-positive, and it is estimated that one in
every eight children is born with HIV [2].
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e-mail: ac@chdr.nlSince 2002 the nation has embarked on the provision of
antiretroviral drugs for all its eligible citizens by imple-
menting the MASA program.(The national antiretroviral
therapy program was given the name MASA, the Setswana
world for “dawn”).
The use of potent antiretroviral combinations has
provided unprecedented opportunities for effectively treat-
ing HIV disease by suppressing viral replication and has led
to dramatic decline in HIV mortality [3, 4].
Adherence to antiviral regimens in HIV infected patients
is essential for adequate suppression of viral replication.
When adherence falls below a certain level, intermittent
viremia will occur, and this may increase the chance of the
development of resistant strains possibly followed by
therapy failure [5–7].
In contrast, nonadherence to the prescribed antiretroviral
regimens is associated with a rapid selection of resistant
HIV strains resulting in treatment failure [8, 9].
The required high level of antiretroviral drug adherence
in a poor resource setting remains therefore a serious
concern. Assessment of adherence in HIV patients such as
in this pilot-study may also provide tools to allow feedback
and education on an individual health care provider–patient
base.
For this reason patients in the Botswana Infectious Disease
CareCenters(IDCC)treatmentprogramareurgedateachvisit
to the IDCC facility to comply with the prescribed ART
regimen. This occurs in three stages: (1) in group instruction
sessions together with other HIV patients and individual
counselling by a trained nurse or pharmacist, (2) by their
individual health care provider (physician), and (3) by the
pharmacist. Inaddition,patientsare usuallyaccompanied bya
close family member who is asked to assist or remind patients
of the pill intake (adherence partner).
Reliable information about the actual tablet intake is a
prerequisite for any form of management or modification of
the adherence to therapy. It has been recognised that many
of the traditional methods of assessing adherence such as
pill counts, diaries, or self-reports are unreliable. Electronic
monitoring enables the recording of the time points of pill
bottle openings. This method also has drawbacks and may
underestimate adherence [10] and, of course, it does not
provide evidence of actual ingestion of the drug [11].
Despite these drawbacks it has been so far the closest to a
gold standard for adherence measuring [12], although other
methods remain of value.
A new method to measure adherence to prescribed
medication regimen is the use of electronic monitoring
[10, 13, 14]. Such systems commonly rely upon a
microprocessor located in the cap of the medication
container, where time and date of each opening are
recorded. Each cap opening and closing is assumed to
reflect a single medication-taking event. The data stored in
the microprocessor are transferred to a computer database
and uploaded for analysis [11]. Other methods like self-
reporting, pharmacy records, and pill counts tend to
overestimate patient adherence by anywhere from 20–30%
[15–21].
This study was designed as a pilot study to evaluate
electronic adherence monitoring in an HIV infected patient
group that was put on antiretroviral medication for the first
time. A secondary objective was to compare the adherence
measured by electronic monitoring with that of self-
reporting by means of a medication diary.
Methods
Patients
Thirty consecutive patients were recruited into the study
during the period 13–30 October 2005. All were patients
with an AIDS-defining illnesses and/or CD4 cell counts<
200 cells/mm
3 (uL) who were offered HAART according to
the Botswana Guidelines on Antiretroviral Treatment [2].
All patients were ARV-naïve.
Design
This was a trial in which treatment-naïve patients were
monitored with regard to adherence to prescribed anti-HIV
medication. Patients were not informed about the use,
blinded of the electronic monitoring system, and were only
asked to return their pill-bottles at each visit to the
pharmacy when they returned for a refill and a consultation.
Patients were also supplied with a self-reporting form. The
study did not involve study related interventions and the
subjects were not required to change behaviour in any way.
The subjects were informed that the medication was
supplied in special containers that had to be returned to
the clinic but not about the monitoring system to prevent
bias. The study was approved by the hospital management
and the chief physician of the department of internal
medicine.
Treatment regimens
The treatment regimen used consisted of 2-nucleoside
reverse transcriptase inhibitors (NRTIs) plus 1 nonnucleo-
side reverse transcriptase inhibitor (NNRTI). Patients
started the recommended first-line treatment with three
different agents. These were zidovudine and lamivudine in
a combination tablet Combivir (CBV) plus efavirenz (EFV)
or nevirapine (NVP).
Male and female patients who were not anaemic were
prescribed Combivir medication whereas anaemic patients
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lamivudine medication. The stavudine dose was adjusted
according to bodyweight (30 or 40 mg).
All patients except females in the reproductive age
category were given once daily EFV. All females of the
former category were prescribed NVP at a 200 mg once
daily dose for 14 days which, after assessing the liver
function parameters, was increased to 200 mg twice daily.
The continuation of NVP or EFV was dependent on the
absence of significant rise in hepatic enzymes (AST and
ALT). Approximately 90% of those who started the NVP or
EFV treatment are able to continue this medication. Patients
returned to the IDCC after a month for a medical check and
refill of their prescription unless clinical events dictated
earlier visits to the clinic.
The treatment starters were booked to see the doctor
after the first 2 weeks of therapy. After seeing the doctor,
the self recorded medication card and the electronic
monitors were collected, and the data stored in the
microprocessor were transferred to a database in the
computer. Following this, each bottle was refilled and
provided with a new label with medication instructions.
Most patients received a refill for a period of 1 month,
some however for a shorter period. The potential side
effects were discussed with each patient. The results of the
first analysis of the electronic monitors were not used in
any counselling.
The electronic monitors were MEMS IV Track Cap
devices (Aardex, Zug, Switzerland) with a MEMS IV
Communicator for read-out of the results.
Study endpoints
The primary study endpoint was the adherence level
measured (over a minimal period of 6 weeks) by the
percentage of days on which the patients took a correct
dosing over the monitored period. Adherence was also
expressed as the number of pill-intakes recorded on a self-
reporting forms designed to reflect the intended schedule
and timing of treatment.
In the event a patient opened his/her bottle more than
was prescribed (surplus opening), it was assumed that the
patient correctly took the prescribed pills. However,
occasions on which a patient opened less than the
prescribed dose frequency were considered as adherence
failures.
Sequence and duration of trial period
Each patient was immediately given counselling and made
familiar with the ART treatment. During the counselling
session emphasis was given with regard to the need of strict
adherence of the prescribed medication and to methods to
prevent disease transmission. They were also informed
about the self-reporting form and given a pen to mark
taking a treatment with a cross.
ART medication was started thereafter and the adherence
to the pill intake schedule was monitored by means of using
electronic monitors and self-recording for a period of
6 weeks. At the start of the treatment, electronic monitors
containing medication for a period of 2 weeks were
provided. After an evaluation by the doctor at day 14 of
treatment the electronic monitors and self-reporting form
were collected and the data in the microprocessor were
entered in the database. The electronic monitors were
subsequently refilled with medication for the next period
of 1 month. A new self-reporting form was also given.
Patients were given 2 (in case of Lamivudine/Zidovu-
dine + NVP or EVF) or 3 electronic monitors (in case D4T,
3TC, and NVP or EFV).
Patients recruited in the study were asked to return the
electronic caps and the self-reporting form on each occasion
of a visit to the IDCC. A self-reporting form was issued at
the start of the study. This form contains rows where the
patient had to mark with x each time they took the pill at
the correct time. As some people in Botswana could not
read or write, this form was kept very basic. A pencil was
given to every patient who participated in the study.
Results
A total of 30 HIV infected adults were enrolled in the study.
In five patients full data could not be obtained because of
various reasons. This leaves an evaluable group of 25
(9 male, 16 female; average age 35.6 years, range 22–55
years). Twenty patients completed the 6-week monitoring
period and the mean follow-up period was 49 days (range
42–72 days).
The reasons for lack of follow-up in the five patients
varied, but in three patients it was due to mortality. In these
three cases, as the relatives or nursing staff did not know
about the value of the medication bottle (due to the blinding
of the patients), the bottles were not returned. One patient
was admitted to hospital where the nursing staff discarded
the pill bottles. One patient failed to return for follow-up.
Full follow-up was not obtained in another five patients for
various reasons. This included technical failure of the
compliance monitor in two cases and a change in the return
date of the subjects who then received a refill in a normal
container. Adherence assessed from the dosing histories
compiled by electronic monitoring are shown in Table 1.
Assuming that surplus opening of the bottles was
associated with correct medication intake, the mean
adherence level was 85% (SD=23%, range 20–100%).
When surplus openings were calculated as incorrect, the
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(data not shown). Seven patients (23%) had an adherence
under 90%, a level at which virological failure increases
substantially [10]. Examples of the medication records
obtained from the electronic monitoring device are shown
in Fig. 1 for a patient with good adherence and a patient
with low adherence to the regimen.
Adherence assessed by means of self-reporting
The mean adherence assessed by means of self-reporting of
medication intake was 98% with two (6%) patients
recording adherence level lower than 90%. Adherence by
self-reporting differed significantly from the adherence
measured by the MEMS monitors method (p<0.05, paired
t-test). Three patients did not hand in their diary.
Discussion
In this pilot study we assessed the use of MEMS monitors
to study the adherence to antiretroviral medication pre-
scribed for HIV patients living in a low resource health care
system. We demonstrated that assessment of adherence with
this technique is feasible and may provide useful results.
There was an approximately 30% drop-out rate of the
recruited patients due to inability to recover data or early
mortality. This may seem unacceptable in a well-resourced
health care system. It is a reality in many countries where
patients present with much more advanced disease, when
there are sometimes great difficulties coming to the
hospital, and patients can often not be reached by telephone
or mail as they do not regularly have a postal address. It is
likely that some association exists between failure to return
Table 1 Adherence (%) of the patients (n=25) by MEMS caps and self-reporting
Patient
number
TC Follow-up
(days)
MEMS Self
report
Lamivudine /
zidovudine (bd)
EFV
(od)
Lamivudine
(bd)
NVP
(od/bd)
d4T
(bd)
Drop out/
non-retrievel
1 1 11 100 100 100 100 3
2 2 70 95 100 91 100
3 2 14 100 No data 100 100 3
4 1 51 98 100 98 100
54 −− − − − − − − 1
6 1 44 71 100 71 95
7 3 45 73 70 92 81 96
8 1 44 100 100 100 100
9 2 44 98 100 100 98
10 2 14 100 100 100 100 3
11 1 44 88 100 88 98
12 2 43 93 100 93 93
13 1 44 98 89 98 100
14 1 −− − − − − − − 2
15 2 44 93 100 98 93
16 2 15 62 100 100 62 3
17 2 −− − − − − − − 2–1
18 2 44 84 100 84 86
19 2 45 98 100 98 100
20 1 9 100 No data 100 100 3
21 1 −− − − − − − − 1
22 1 72 75 100 75 94
23 2 44 21 100 21 29
24 2 42 93 100 93 95
25 2 66 97 100 100 97
26 1 43 100 100 100 100
27 1 −− − − − − − − 4
28 1 49 94 No data 96 96
29 1 56 100 100
30 1 47 20 100 20 100
avg 42 85 98 89 98 92 87 96
Treatment codes (TC) are: 1 Lamivudine/zidovudine, Efavirenz (EFV); 2 Lamivudine/Zidovudine, Nevirapine (NVP); 3 Lamivudine, Nevirapine
and stavudine (d4T); and 4 Lamivudine and Efavirenz. MEMS indicates the data combined for all different treatments. Patient numbers are not
consecutive because patients who died have been omitted. Reasons for drop out and nonretrieval: 1 death; 2 MEMS thrown away; 3 missed by
investigator (patients showed up on another date than the investigator expected); and 4 lost to follow-up
1118 Eur J Clin Pharmacol (2007) 63:1115–1121to the hospital and adherence to the drug regimen and the
current patient set therefore may reflect an overestimation
of adherence.
Self-reporting of medication intake has been shown to be
less reliable than the MEMS monitors [22, 23]. Therefore,
it is not surprising that patients recorded adherence levels
which were considerably higher compared with those
assessed by the presumably more objective electronic
monitors. Clearly, none of the methods used to measure
adherence record actual intake of medication, and there are
even indications that at least in some instances self-
reporting is a more accurate record of adherence [24].
Despite these findings we consider the MEMS monitors
more appropriate for a developing country with a larger
potential for illiteracy. Patients knowledge about the
monitoring of compliance will likely affect the absolute
level of compliance [25], but there are no reasons why the
relative ranking of compliance amongst patient groups is
affected, and the device can still be used to improve
adherence. In this study we chose not to inform the patients
about the use of the monitoring device.
One of the critics often cited about the electronic monitor
is that the opening of the bottle does not prove ingestion.
However, it has been shown recently that projected plasma
Patient 2 / Combivir (2xd) / Nevirapine (1xd 2xd)
Dosing Date
D
o
s
i
n
g
 
T
i
m
e
Combivir (2xd)
Nevirapine (1xd 2xd)
03:00    
06:00    
09:00    
12:00    
15:00    
18:00    
21:00    
24:00    
03:00    
0 7 14 21 28 35 42
start 1st-return, day-14
refill, day-14
2nd-return, day-42
Info: This patient got a refill but will come back after I left the country-> No bottles
All Medications
Pct Correct=85%
Not monitored/counted
Exact dosing
Skip one out of two
No dosing
Overdosing
Combivir (2xd)
3 2 2 3 2 2 2 2 2 2 2 2 1 1 6 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2
Pct Correct=90%
Nevirapine (1xd 2xd)
 0 1 1 2 1 2 1 1 1 1 1 2 2 2 8 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Pct Correct=87.5%
Patient 23 / Combivir (2xd) / Nevirapine (1xd 2xd)
Dosing Date
D
o
s
i
n
g
 
T
i
m
e
Combivir (2xd)
Nevirapine (1xd 2xd)
03:00    
06:00    
09:00    
12:00    
15:00    
18:00    
21:00    
24:00    
03:00    
0 7 14 21 28 35 42
start 1st-return, day-14
refill, day-14
2nd-return, day-44
All Medications
Pct Correct=14.3%
Not monitored/counted
Exact dosing
Skip one out of two
No dosing
Overdosing
Combivir (2xd)
5 3 2 2  0 2 2 1 1 2  0 2 1 2 2 1  0  0  0  0  0  0  0  0  0 1 2  0  0  0  0  0  0 1  0  0  0  0  0  0  0  0  0  0 1
Pct Correct=19%
Nevirapine (1xd 2xd)
6 1 1 3  0 1 1 1 1 2  0 1 1 1 2 1  0  0  0  0  0  0  0  0  0 1 2  0  0  0  0  0  0 1  0  0  0  0  0  0  0  0  0  0 1
Pct Correct=23.8%
Fig. 1 Examples of data of
from patients with good and
respectively poor adherence
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histories correlates very well with directly measured
concentrations [26]. It has also been shown that t in HIV
patients electronically compiled dosing histories strongly
correlates with viral suppression or the occurrence of
virological failure [27]. It is therefore assumed that this
method is a fair reflection of medication intake [28]. In this
small study performed in HIV patients, some subjects
opened their bottles more often than needed (surplus
opening). Such surplus opening was not considered as
nonadherence (in that case our reported adherence level
would be lower). If surplus opening had led to extra intake
of medication, it would not have contributed the endpoints
of virological failure or the induction of resistance. We
assume, therefore, that such surplus opening of the pill
bottles had occurred for other reasons. Surplus openings
occurred especially in the group of patients that had to take
a once daily regimen together with twice daily regimens.
These extra openings occurred often at the same time as
when the prescribed twice-daily regimen was taken. This
may have occurred because the patients were unsure about
which bottle belonged to which medication. This may
indicate that clearer labelling is essential, especially in an
illiterate society. Under-opening most likely reflects non-
adherence, although it cannot be excluded that in some
cases patients removed several tablets at the same time.
However, such behaviour is highly likely to increase the
chance of erroneous medication intake and was for this
reason registered as nonadherence.
Several studies have indicated that medication adherence
lower than approximately 90% increases the chance of
virological failure and the development of resistant virus
strains [12, 28, 29]. The result of this pilot study indicates
that even after careful counseling and guidance, a signifi-
cant number of patients did not manage to adhere suf-
ficiently to the twice-daily pill intake regimen. This
observation study was too short to allow an analysis of
the clinical impact of the observed low adherence in such
patients on the development of virological failure. Addi-
tionally, reliable measurement of viral load was impossible
in the hospital. However, our data did help to identify some
patients with low adherence at the start of treatment and
allowed a diversion of scarce resources for extra counseling
for such patients.
The outcome of monitoring pill intake by the electronic
monitors may therefore assist in timely counseling of
patients with regard to their medication intake and
persistence with the prescribed regimen.
Adherence measurements by means of using electronic
monitors together with self and adherence partner recording
of pill intake are likely to be useful in a much needed larger,
long-term and more comprehensive adherence study in a
low-resource health-care-system setting. Such a study can
contribute to directed efforts to optimise the treatment of
HIV-infected patients worldwide.
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